engleski

A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors

Aim: Assessment of clinical and biochemical efficacy of the octreotide in the treatment of patients with functional neuroendocrine tumors (NETs). Patients and Methods: The study included 14 patients treated with octreotide for 6 months. They were diagnosed with VIPoma, glucagonoma, gastrinoma, medullary thyroid carcinoma (solitary and as a part of MEN-II syndrome), pancreatic carcinoids (solitary and as a part of MEN I syndrome) and midgut carcinoids, and presented with Verner-Morrison, glucagonoma, Zollinger Ellison and carcinoid syndrome respectively. All of the patients had a metastatic disease at the time of diagnosis and a positive octreoscan finding. Initially elevated chromogranin A levels were detected in 11 (78.6%) and elevated 5-HIAA levels in 8 (57.1%) patients. Symptomatic efficacy assessments were made by diarrhea reductions during treatment course, and laboratory efficacy was assessed through changes in 5-HIAA and chromogranin A levels. Assessments were made initially and following 6 months of therapy. Results: Median urinary 5-HIAA and the number of stools decreased significantly (p=0.016 and p=0.009 respectively at p<0.05) while chromogranin A levels had the decreasing tendency but not statistically significant (p=0.14). There was a positive correlation between the 5-HIAA reduction and the decrease in stool number at baseline and during treatment course (p<0.05). No correlation was observed between 5-HIAA and CgA levels and also there was no correlation between CgA reduction and symptomatic improvement. Conclusion: Octreotide proved to be effective in reducing symptoms and biochemical markers associated with hypersecretory syndromes of GEP-NETs.

gastroenteropancreatic neuroendocrine tumors; carcinoid syndrome; hypersecretory syndromes; octreotide; 5-hydroxyindolacetic acid; chromogranin A

nije evidentirano